`571-272-7822
`
`Paper 66
`Entered: March 29, 2018
`
`
`
`
`
`
`APOTEX INC., APOTEX CORP.,
`ARGENTUM PHARMACEUTICALS LLC,
`ACTAVIS ELIZABETH LLC, TEVA PHARMACEUTICALS USA, INC.,
`SUN PHARMACEUTICAL INDUSTRIES, LTD.,
`SUN PHARMACEUTICAL INDUSTRIES, INC., and
`SUN PHARMA GLOBAL FZE,
`Petitioners,
`
`v.
`
`NOVARTIS AG.,
`Patent Owner.
`____________
`
`Case IPR2017-008541
`Patent US 9,187,405 B2
`_______________
`
`
`Before CHRISTOPHER M. KAISER and ROBERT A. POLLOCK,
`Administrative Patent Judges.
`
`POLLOCK, Administrative Patent Judge.
`
`
`ORDER
`Conduct of the Proceeding
`37 C.F.R. § 42.5
`
`
`
`
`
`
`
`1 Cases IPR2017-01550, IPR2017-01946, and IPR2017-01929 have been
`joined with this proceeding.
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`A conference call in the above proceedings was held on March 29, 2018,
`among counsel for the respective Petitioners, Patent Owner, and Judges Pollock
`and Kaiser to discuss issues raised in the parties emails of March 28, 2018.
`Ex. 3010 (Petitioner’s email); Ex. 3011 (Patent Owner’s email and attached
`correspondence between the parties); Ex. 3012 (attachments from Ex. 3011).
`Petitioner engaged a court reporter for the call. Petitioner will submit a copy of the
`transcript as an exhibit, which, in conjunction with this Order, will serve as the
`official record of the call.
`Petitioner seeks permission to file a motion to strike Patent Owner’s Sur
`Reply (Paper 63) or, in the alternative, an opportunity to submit responsive
`briefing with supporting evidence on an adjusted schedule, because Patent Owner
`allegedly exceeded the scope of argument permitted in our Order of February 23,
`2018 (Paper 54). Having reviewed the transcript of our February 21, 2018
`teleconference (Ex. 2094) and related correspondence (Ex. 3004), we conclude that
`the phrasing of our Order in paper 54 was imprecise and overly narrow. Although
`Patent Owner should have brought this to our attention prior to filing its sur reply,
`it has, nevertheless, reasonably interpreted the intended scope of our order.
`Accordingly, Petitioner’s request for a motion to strike is denied.
`Petitioner’s request to submit responsive briefing with supporting evidence
`is also denied. The thrust of Patent Owner’s sur reply goes to the testimony of
`Dr. Benet, Petitioner’s expert in pharmacology. As Patent Owner points out,
`Petitioner had the opportunity to advance such an expert in its Petition but chose
`not to do so until its Reply. At this stage of the proceeding, additional briefing
`would require further adjustment of the schedule and additional rounds of
`depositions which would be unduly disruptive. Petitioner will have ample
`
` 2
`
`
`
`
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`opportunity to challenge the opinions of Patent Owner’s experts in the upcoming
`depositions.
`Petitioner further seeks authorization to file a sur-reply to Paper 64, Patent
`Owner’s Reply regarding its Contingent Motion to Amend. Having considered the
`parties’ arguments on this matter, we conclude that the request is reasonable.
`Although this, too, threatens to disrupt the trial schedule, we grant Petitioner’s
`request on an accelerated basis. Petitioner may have 12 pages to respond.
`Petitioner’s sur reply shall be filed no later than the close of business on April 19,
`2018. Further, any experts submitting testimony in support of Petitioner’s sur
`reply shall be made available no later than 10 business days after the filing of the
`sur reply. Upon failure to do so, Patent Owner may request that we order
`Petitioner to show cause why the supporting expert testimony should not be struck.
`Finally, considering the posture of this case, we grant Petitioner’s request
`that the ten-page limit on observations on cross-examination will apply on a per-
`witness basis.
`
`
`SO ORDERED
`
`
`
`FOR PETITIONER APOTEX:
`
`Steven W. Parmelee
`Michael T. Rosato
`Jad A. Mills
`WILSON SONSINI GOODRICH & ROSATI
`sparmelee@wsgr.com
`mrosato@wsgr.com
`jmills@wsgr.com
`
` 3
`
`
`
`
`
`
`
`IPR2017-00854
`Patent 9,187,405 B2
`
`FOR PETITIONER ARGENTUM:
`
`Teresa Stanek Rea
`Deborah H. Yellin
`Shannon M. Lentz
`CROWELL & MORING LLP
`trea@crowell.com
`dyellin@crowell.com
`slentz@crowell.com
`
`Tyler C. Liu
`ARGENTUM PHARMACEUTICALS, LLC
`tliu@agpharm.com
`
`FOR PETITIONER TEVA:
`
`Amanda Hollis
`Eugene Goryunov
`KIRKLAND & ELLISLLP
`amanda.hollis@kirkland.com
`egoryunov@kirkland.com
`
`FOR PETITIONER SUN PHARMA:
`
`Samuel Park
`WINSTON & STRAWN LLP
`spark@winston.com
`
`FOR PATENT OWNER:
`Jane M. Love
`GIBSON, DUNN & CRUTCHER LLP
`jlove@gibsondunn.com
`
`
`
`
`
`
`
`
`
` 4
`
`
`
`
`
`